The Pharmerging market is estimated to represent a global market of USD 690.3 billion by 2019 with growth rate of 18.8%.
The pharmerging industry covers the study for developing countries where the use of pharmaceuticals is rapidly growing and is projected to experience strong growth in the future period. Countries such as China, India, Brazil, Russia, and South Africa among others are considered under the research scope. Drug spending in these economies is increasing at a constant rate, making them attractive targets for drug manufacturers to invest in. For instance, as per the International Federation of Pharmaceutical Manufacturers & Associations, pharmerging economies account for around 50% of absolute growth in drug spending every year.
Key Vendor Takeaway
Companies namely Pfizer, Inc., AstraZeneca, Roche, GE Healthcare, and Medtronic are actively operating in this industry. Attributes such as company overview, financials, product benchmarking and key initiatives were discussed separately. Key players are engaged in strategic collaborations to capture untapped market opportunities. For instance, in July 2017, AstraZeneca collaborated with Merck, Inc. to potential cancer therapeutic, MEK and PARP inhibitors in combination with PD-L1 medicines.
There is a constant rise of people affected by chronic disorders due to the lifestyle changes. The number of cardiovascular, cancer, respiratory and diabetes patients are increasing monumentally. For example, cardiovascular conditions such as strokes, coronary heart disease, rheumatic heart disease, and cardiomyopathy are expected to be the major causes of mortality and morbidity in developing countries across the world. As per the World Health Organization statistics, more than 80% of cardiovascular deaths occur in low to middle-income countries. Additionally, an aging population, higher standards of living and advancement in technologies in the medical sector have led to a sharp increase in life expectancy. As a consequence, longer-lived individuals will create upward pressure on demand for pharmaceuticals & healthcare services. All such facts would in turn open up a new market for healthcare treatment that have traditionally been targeted at developed region patients.
The sudden challenges created by the ongoing COVID-19 outbreak are well-captured to exhibit the long term pharmerging market growth projections. The pharmerging industry growth sectors are identified with precision for a better growth perspective considering the political, economical and social impact of COVID-19 virus ourbreak.
Product Types Takeaway
In terms of product types, the industry is divided into Pharmaceuticals and Healthcare. Pharmaceuticals segment is further categorized as Patented, Generic and Over-the-Counter Therapeutics. In 2017, generic pharmaceuticals recorded USD 198.7 billion and the segment is projected to grow with strong CAGR during the future period. Healthcare segment is bifurcated as Medical Devices, In-Vitro Diagnostics, and others.
Geographically, the industry is broadly categorized into Tier I, Tier II and Tier III economies. Chinese pharmerging market covers under the Tier I category which is considered one amongst the highest revenue generating country. In 2017, this category has captured over 52% of the worldwide market. According to China’s Ministry of Finance (MOF), healthcare expenditure in the country has increased by 10% in 2016. Due to this fact, out-of-pocket spending for healthcare needs in China has decreased, as the penetration of insurance has increased. As of 2015, almost 95.0% of the population is enrolled in at least one public health insurance scheme.
Tier II category include a detailed study for BRICS countries (except China) such as India, Russia, Brazil and South Africa. India and Brazil collectively accounted for over 60% revenue share of the countries considered under Tier II economy. As per the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), the national pharmaceutical exports are projected to reach USD 20 million by 2020. The Indian pharmaceutical sector is highly fragmented with the presence of more than 15,000 manufactures. Tier III includes extensive qualitative and quantitative study for Turkey, Poland, Mexico, Argentina, Thailand, and Saudi Arabia. These countries represent a wide range of incomes, and GDP Mexico recorded USD 22.9 billion in 2017 and is projected to grow by over 8% CAGR during the study period.
The scope of this report covers the market by its major segments, which include as follows:
PHARMERGING MARKET, BY PRODUCT TYPES
PHARMERGING MARKET, BY REGION
Table of Content
- PHARMERGING MARKET OVERVIEW
- EXECUTIVE SUMMARY
- PHARMERGING KEY MARKET TRENDS
- PHARMERGING INDUSTRY STUDY
- PHARMERGING MARKET LANDSCAPE
- PHARMERGING MARKET – BY PRODUCT TYPES
- PHARMERGING MARKET– BY GEOGRAPHY
- KEY VENDOR ANALYSIS
- 360 DEGREE ANALYSTVIEW
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.
Ph: +162 825 80070 (US)
Ph: +44 203 500 2763 (UK)